Opportunity Information: Apply for PAR 13 148
Apply for PAR 13 148
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Biomarkers for Older Controls at Risk for Dementia (BIOCARD) Study (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Apr 1, 2013 and posted on Mar 21, 2013.
- Applicants must submit their applications by May 25, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Application is limited to Johns Hopkins University, current sponsor of BIOCARD. Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Limited Competition Biomarkers for Older Controls at Risk for Dementia (BIOCARD) Study (U19)" (PAR 13-148), is a National Institutes of Health (NIH) grant announcement designed to support the continuation of the BIOCARD Study through a cooperative agreement mechanism (U19). The central aim is not to launch a brand-new multi-site competition, but to keep a long-running and unusually information-rich dementia-risk cohort going for an additional five-year period. The announcement is explicitly framed as a limited competition, meaning it is only open to the current BIOCARD sponsor at Johns Hopkins University, which is named as the sole eligible applicant. The program sits within NIH's aging research portfolio (CFDA 93.866) and does not require cost sharing or matching funds.
The scientific and public health rationale for the award is tied to the exceptional value of the BIOCARD cohort for Alzheimer's disease (AD) and dementia research. BIOCARD follows older adults who are at elevated risk for developing AD, including many participants who have already begun to show early dementia-related changes. What makes this cohort stand out is the depth and duration of longitudinal data collection. The study includes nearly two decades of repeated clinical evaluations and neuropsychological testing, along with plasma samples collected over that same long timeframe. In addition, the cohort includes about 15 years of structural MRI imaging data and cerebrospinal fluid (CSF) samples. Together, these repeated measures allow researchers to investigate how biological markers and brain changes evolve before and during the earliest symptomatic stages of cognitive impairment, which is a core need in AD research because interventions are widely believed to be more effective when applied early in the disease process.
Mechanistically, the U19 is a cooperative agreement, which typically indicates substantial NIH programmatic involvement compared with standard research project grants. In practical terms, this often means the funded team and NIH staff work more closely on coordination, oversight, milestones, and ensuring the resource continues to serve broader scientific goals. The FOA's stated purpose is to allow BIOCARD investigators to submit a continuation application for another five-year funding period, and it also notes that resubmissions and possible future revision applications are part of the pathway. At the same time, the FOA includes a key limitation for revisions: any revision application cannot request support that extends beyond the project end date of the parent U19 award. That language is meant to keep supplements or scope adjustments tied to the existing award timeline rather than turning revisions into de facto extensions.
Eligibility rules are narrow and explicit. Only Johns Hopkins University, as the current sponsor of BIOCARD, may apply under this announcement. Non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, the FOA allows "foreign components" as defined by the NIH Grants Policy Statement, which generally means certain elements of the project may be carried out internationally when scientifically justified and appropriately structured, even though the applicant institution itself must be U.S.-based and, in this case, specifically Johns Hopkins.
From an administrative standpoint, the opportunity was posted March 21, 2013, created April 1, 2013, and lists a closing date of May 25, 2016 (with an archive date of June 25, 2016). The NIH Office of Extramural Research (OER) provides support contacts for access or linking issues via the OER webmaster email. The full announcement was hosted through NIH's funding opportunity system at the link provided in the source text.
In short, PAR 13-148 is a continuation-focused, institution-restricted NIH cooperative agreement opportunity intended to preserve and further develop the BIOCARD longitudinal cohort and its extensive clinical, cognitive, biospecimen, and neuroimaging data. The broader value is that these long-term, repeated measures in a high-risk aging population create a powerful platform for identifying and validating biomarkers that track the earliest changes associated with Alzheimer's disease and related dementias, supporting both scientific discovery and the long-term goal of earlier, more accurate detection and improved prevention or treatment strategies.
Frequently Asked Questions (FAQs)
What is the title and identifier of this funding opportunity?
The opportunity is titled "Limited Competition Biomarkers for Older Controls at Risk for Dementia (BIOCARD) Study (U19)" and is identified as PAR 13-148.
Which agency is offering this grant opportunity?
This is a National Institutes of Health (NIH) funding opportunity within NIH's aging research portfolio.
What type of NIH funding mechanism is being used?
The award uses a cooperative agreement mechanism (U19), which typically involves substantial NIH programmatic involvement compared with a standard research grant.
Is this a brand-new competition to start a new study?
No. The central purpose is to support the continuation of the existing BIOCARD Study for an additional five-year period, not to launch a new multi-site competition.
What is the main purpose of the funding under PAR 13-148?
The stated purpose is to allow the BIOCARD investigators to submit a continuation application to keep the long-running BIOCARD cohort and its unusually rich longitudinal resource going for another five-year funding period.
Why is this opportunity described as a "limited competition"?
It is explicitly framed as a limited competition because it is only open to the current BIOCARD sponsor, Johns Hopkins University, which is named as the sole eligible applicant.
Who is eligible to apply?
Only Johns Hopkins University, as the current sponsor of BIOCARD, is eligible to apply under this announcement.
Are foreign (non-U.S.) institutions eligible to apply?
No. Non-U.S. (foreign) institutions are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible to apply?
No. Non-U.S. components of U.S. organizations are also not eligible to apply.
Does the FOA allow any international work at all?
Yes. While the applicant institution must be U.S.-based (and in this FOA, specifically Johns Hopkins University), the FOA allows "foreign components" as defined by the NIH Grants Policy Statement when scientifically justified and appropriately structured.
Does this opportunity require cost sharing or matching funds?
No. The announcement states that cost sharing or matching funds are not required.
What is the CFDA number associated with this program?
The CFDA number listed is 93.866.
What is BIOCARD and what population does it follow?
BIOCARD is a longitudinal cohort study of older adults who are at elevated risk for developing Alzheimer's disease (AD), including participants who have already begun to show early dementia-related changes.
What makes the BIOCARD cohort scientifically valuable according to the announcement?
The FOA highlights the cohort's exceptional depth and duration of longitudinal data collection, including nearly two decades of repeated clinical evaluations and neuropsychological testing, long-term plasma collection, and extensive MRI and CSF sampling over many years.
What types of data and biospecimens are included in the BIOCARD Study resource?
As described, the study includes repeated clinical evaluations and neuropsychological testing, plasma samples collected over nearly two decades, about 15 years of structural MRI imaging data, and cerebrospinal fluid (CSF) samples.
How long has BIOCARD been collecting longitudinal data?
The FOA describes nearly two decades of repeated clinical and neuropsychological data and plasma samples, along with about 15 years of structural MRI data and CSF samples.
What scientific questions is this continuation intended to support?
The continuation supports research into how biological markers and brain changes evolve before and during the earliest symptomatic stages of cognitive impairment, helping identify and validate biomarkers relevant to Alzheimer's disease and related dementias.
Why is early-stage biomarker research emphasized in this FOA?
The announcement notes a core need in Alzheimer's research: interventions are widely believed to be more effective when applied early in the disease process, which increases the value of biomarkers that track the earliest changes.
What does the cooperative agreement (U19) imply for how NIH will be involved?
The FOA indicates the U19 is a cooperative agreement, which typically means NIH staff and the funded team work more closely on coordination, oversight, milestones, and ensuring the resource continues to serve broader scientific goals.
How long is the continuation period described in the FOA?
The FOA is intended to support continuation of the BIOCARD Study for an additional five-year period.
Does the FOA mention anything about resubmissions or revisions?
Yes. It notes that resubmissions and possible future revision applications are part of the pathway.
Is there a limitation on what a revision application can request?
Yes. The FOA specifies that any revision application cannot request support that extends beyond the project end date of the parent U19 award.
What does the revision limitation mean in practical terms?
Based on the FOA language provided, revisions (supplements or scope adjustments) must remain tied to the existing award timeline and cannot be used to extend support beyond the parent project's end date.
When was this opportunity posted and created?
It was posted on March 21, 2013, and created on April 1, 2013.
What are the closing and archive dates listed for this FOA?
The closing date is listed as May 25, 2016, and the archive date is June 25, 2016.
Where can applicants find the full announcement?
The full announcement was hosted through NIH's funding opportunity system at the link referenced in the source text.
Who is listed as a support contact for access or linking issues?
The NIH Office of Extramural Research (OER) provides support contacts for access or linking issues via the OER webmaster email.
What is the public health rationale for continuing BIOCARD according to the FOA summary?
The rationale is that BIOCARD provides a powerful, long-term platform for identifying and validating biomarkers that track the earliest Alzheimer's-related changes, supporting the goals of earlier, more accurate detection and improved prevention or treatment strategies.
Browse more opportunities from the same category: Health
Next opportunity: FY 2013 CIG CARIBBEAN AREA
Previous opportunity: Limited Competition Dominantly Inherited Alzheimer Network (U19)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 148
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 148) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Organizations for Chronic Disease Prevention Apply for CDC RFA DP10 10080401SUPP13 Funding Number: CDC RFA DP10 10080401SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $230,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 13 149 Funding Number: PAR 13 149 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 13 150 Funding Number: PAR 13 150 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 13 151 Funding Number: PAR 13 151 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Aging Research Dissertation Awards to Increase Diversity (R36) Apply for PAR 13 152 Funding Number: PAR 13 152 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Characterization of Animal Models for Aging Research (R01) Apply for PA 13 155 Funding Number: PA 13 155 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Characterization of Animal Models for Aging Research (R21) Apply for PA 13 156 Funding Number: PA 13 156 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Using Evidence from Science and Community Practice to Develop Web and other Technology Based Tools for HIV Treatment Service Provider Organizations to Improve Linkage, Retention, and Re Engagement of HIV Positive Persons in Care Apply for CDC RFA PS13 1311 Funding Number: CDC RFA PS13 1311 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Drug Target Development and Validation for Antimicrobial Resistant Pathogens (R21/R33) Apply for RFA AI 13 019 Funding Number: RFA AI 13 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01) Apply for RFA AA 13 003 Funding Number: RFA AA 13 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R21) Apply for RFA AA 13 004 Funding Number: RFA AA 13 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Functional Characterization of Oral Cancer Initiating Cells (R01) Apply for RFA DE 14 001 Funding Number: RFA DE 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Functional Characterization of Oral Cancer Initiating Cells (R21) Apply for RFA DE 14 002 Funding Number: RFA DE 14 002 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| KNOWLEDGE FOR HEALTH II Apply for SOL OAA 13 000048 Funding Number: SOL OAA 13 000048 Agency: Agency for International Development Category: Health Funding Amount: $40,000,000 |
| Using Traditional Foods and Sustainable Ecological Approaches for Health Promotion and Diabetes Prevention in American Indian/Alaska Native (AI/AN) Communities CC RFA DP08 819 Apply for CDC RFA DP13 1317 Funding Number: CDC RFA DP13 1317 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Delta Health Care Services Program Apply for RBS01 2012 DHCS Funding Number: RBS01 2012 DHCS Agency: Business and Cooperative Programs Category: Health Funding Amount: Case Dependent |
| Alcohol Use Disorders Treatment, Services, and Recovery Research (R01) Apply for PA 13 160 Funding Number: PA 13 160 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Use Disorders Treatment, Services, and Recovery Research (R21) Apply for PA 13 161 Funding Number: PA 13 161 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Alcohol Use Disorders Treatment, Services, and Recovery Research (R03) Apply for PA 13 162 Funding Number: PA 13 162 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Program to Support New Implementation of State or Territorial Public Health Laboratory Capacity for Newborn Bloodspot Screening of Severe Combined Immunodeficiency (SCID) Apply for CDC RFA EH13 1303 Funding Number: CDC RFA EH13 1303 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 148", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.